PIK-108

• Description:

  PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor[1].

• UNSPSC:

  12352005

• Target:

  PI3K

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pik-108.html

• Purity:

  99.05

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C1C=C(N2CCOCC2)OC3=C(C(NC4=CC=CC=C4)C)C=C(C)C=C13

• Molecular Formula:

  C22H24N2O3

• Molecular Weight:

  364.44

• References & Citations:

  [1]Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125 (4) :733-47.|[2]Jack S Chen, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther. 2008 Apr;7 (4) :841-50.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [901398-68-3]